Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company. The company focuses on exploring new methods of use of alpha-1 antitrypsin (AAT). AAT is a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood (p-AAT) to treat patients suffering from emphysema due to AAT-deficiency. The company holds licenses for method of use issued patent claims for the use of p-AAT in the treatment of diabetes, certain bacterial and viral diseases and cellular transplantation and graft rejection, which include reducing the risk of a non-organ transplant rejection, reducing the risk of developing graft versus host disease (GvHD) and for treating GvHD in patients who have received a cornea, bone marrow, stem cell or pancreatic islet cell transplant. In addition, the company holds licenses for method of use patent application claims for the use of p-AAT in the treatment of radiation protection and myocardial remodeling. The company also holds a license to an issued method of use patent owned by a privately-held company for the treatment of diabetes using p-AAT. In 2011, the company began funding research and development of a synthetic form of AAT (Fc-AAT). In 2013, the company chose a specific form of the Fc-AAT molecule as its lead molecule (Fc-AAT 2) and is placing it into preclinical development. License and Sponsored Research Agreements Fc-AAT: The company holds an exclusive license with Regents of the University of Colorado (RUC) covering patent applications covering composition of matter and methods of use for various Fc-AAT constructs. Bacterial Disorders: The company holds an exclusive license with RUC covering a patent and patent applications for the use of p-AAT in the treatment and/or prevention of certain bacterial disorders. The Bacterial License also includes patent applications covering composition of matter and methods of use for its Fc-AAT 2 construct. Viral Disorders: The company holds a license with RUC covering patents and patent applications for the use of p-AAT in the treatment and/or prevention of certain viral disorders. Cellular Transplantation: The company holds an exclusive license with RUC covering patent applications for the use of p-AAT in the treatment of cellular transplantation rejection and graft rejection. The company is pursuing patent rights under this license agreement for the treatment of cellular transplantation and graft rejection disorders, including GvHD, in the U.S., Canada, and Europe. Diabetes: The company holds a license to an issued patent for the treatment of diabetes (Types 1 and 2) using p-AAT (the Diabetes Patent) with Bio Holding, Inc. (Bio Holding). Research and Development As of March 31, 2014, the company incurred approximately $163,000, on research and development expenses.
omni bio pharmaceutical inc
(OMBP:OTC Markets Group Inc - No Information)
181 West Boardwalk
Fort Collins, CO 80525
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for OMBP.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact OMNI BIO PHARMACEUTICAL INC, please visit www.omnibiopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.